



L'EMATOLOGIA "SERÀGNOLI"
E LA SCUOLA EMATOLOGICA BOLOGNESE:
UNA STORIA DI 50 ANNI

Mieloma Multiplo e Amiloidosi AL

B Bruno


*Divisione Universitaria di Ematologia
AOU Città della Salute e della Scienza di
Torino
Università di Torino*



Disclosures of Benedetto Bruno

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Astrazeneca	x				x		
Roche					X	X	
Gilead					X		
Novartis					X		
Jazzpharma					X	X	
GSK					X	X	
Incyte					X		
Janssen	X				X	X	
BMS					X	X	
Beigene					X		
Amgen					X	x	
Pierre Fabre						X	

La sopravvivenza dei pazienti affetti da Multiplo è più che quintuplicata nelle ultime decadi!




Adapted from Puertas B et al, Cancers 2023, 15, 1558



Historical overview on the treatment landscape

Timeline of drug discovery




^a2015, 55% (modelled)

ADC, antibody–drug conjugate; CAR, chimeric antigen receptor; IMiD, immunomodulatory drug; mAb, monoclonal antibody; MM, multiple myeloma; OS, overall survival.

1. Shah UA, Mailankody S. *BMJ* 2020;370:m3176; 2. Moreau P, et al. *Ann Oncol* 2017;28(suppl. 4):iv52–iv61.




Anno 2000



Auto-Allo Tx








Measurable Residual Disease (MRD) in Multiple Myeloma


as a prognostic marker¹

~ 100 publications supporting MRD effect on PFS/OS, 4 metanalysis published

Single strongest prognostic tool in Multiple Myeloma



as an adaptive treatment tool²



1. Munshi NC et al. Blood Adv 2020; 2. Sonneveld P et al. Nejm 2024;

as an endpoint in clinical trials



On April 12, 2024, FDA ODAC voted 12-0 in favor of using MRD as an accelerated approval endpoint in MM clinical trials following 2 meta-analyses conducted by i2TEAMM and University of Miami

in clinical practice



NEXT GENERATION FLOW NEL MIELOMA MULTIPLO: DATI PRELIMINARI DI UN'ESPERIENZA MULTICENTRICA PER L'ARMONIZZAZIONE DELLA METODICA NELLA PRATICA CLINICA

E. Saraci, S. Oliva, V. Trimarco, M. Chiarini, N.L. Parrinello, R. Zambello, I. Cordone, S. Masi, G. Rossi, S. Marino, A.M. Triolo, A. Roccaro, A.M. Carella, F. Buccisano, A. Belotti, M.I. Consalvo, A. Romano, A. Tonini, S. Mercadante, B. Bruno, C. Terragna, E. Zamagni (Torino, Padova, Brescia, Catania, Roma, San Giovanni Rotondo-FG, Bologna)

SIES 2024

What is AL Amyloidosis?



AL amyloidosis is caused by a bone marrow disorder. Misfolded proteins can accumulate in the body's tissue, nerves and/or organs, gradually causing damage and affecting function.

Symptoms may include:

www.amyloidosis.org

Treatments of AL Amyloidosis

Antibodies (against Plasma cells)	Proteasome Inhibitors	iMiDs	Alkylating	Steroids
Daratumumab	Bortezomib	Thalidomide	Oral Melphalan	Dexametasone
Isatuximab	Carfilzomib	Lenalidomide	IV Melphalan (auto-transplant)	Prednisone
Elotuzumab	Ixazomib	Pomalidomide	Cyclophosphamide	

Combination Regimen

Dar atumumab	Cyc lophosphamide	Bort ezomib	Dex ametasone
---------------------	--------------------------	--------------------	----------------------

Kastritis E et al., N Engl J Med. 2021;385:46-58



**Thank you !
Grazie !**



**UNIVERSITÀ
DI TORINO**